Multikinase inhibitors in thyroid cancer

Ann Oncol. 2012 Sep:23 Suppl 10:x328-33. doi: 10.1093/annonc/mds356.
No abstract available

Publication types

  • Congress
  • Overall

MeSH terms

  • Adenocarcinoma, Follicular* / drug therapy
  • Adenocarcinoma, Follicular* / pathology
  • Carcinoma, Medullary / congenital*
  • Carcinoma, Medullary / drug therapy
  • Carcinoma, Medullary / pathology
  • Carcinoma, Neuroendocrine
  • Carcinoma, Papillary* / drug therapy
  • Carcinoma, Papillary* / pathology
  • Clinical Trials as Topic
  • Dacarbazine / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Iodine Isotopes / therapeutic use
  • Molecular Targeted Therapy
  • Multiple Endocrine Neoplasia Type 2a* / drug therapy
  • Multiple Endocrine Neoplasia Type 2a* / pathology
  • Neoplasm Metastasis
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Thyroid Neoplasms* / drug therapy
  • Thyroid Neoplasms* / pathology

Substances

  • Iodine Isotopes
  • Protein Kinase Inhibitors
  • Dacarbazine
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf

Supplementary concepts

  • Familial medullary thyroid carcinoma
  • Papillary Thyroid Microcarcinoma
  • Thyroid cancer, medullary